Annals of neurology · 2026
Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease.
Редакционная статьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Siderowf Andrew, Heathers Laura E A, Fabrizio Kimberly, Kuhl Maggie McGuire, Kopil Catherine M, Flagg Emily, McMahon Bridget A, Coffey Christopher S, Bright Audra, Totten Michelle, Lemon Lynell P, Bryan Erinn, Prakash Neha, Pavese Nicola, Bloem Bastiaan R, Alcalay Roy N, Mirelman Anat, Stefanis Leonidas, Okubadejo Njideka, Tolosa Eduardo, Tanner Caroline M, Simuni Tanya, Chowdhury Sohini, Tropea Thomas F, Marek Kenneth, Foroud Tatiana, Parkinson's Progression Markers Initiative
Аннотация
The Parkinson's Progression Markers Initiative (PPMI) has remained at the vanguard of Parkinson's disease (PD) research through evolving recruitment strategies that mirror advances in PD biology. PPMI was initially focused on untreated, early-stage PD. Over time, it has expanded to include genetic cohorts, prodromal participants identified via olfactory testing and risk factor questionnaires targeting people with rapid eye movement (REM) sleep behavior disorder (RBD). Most recently, PPMI has focused on the biology underlying PD and sought to recruit individuals defined by neuronal alpha-synuclein disease (NSD) biomarkers. This evolution from clinical to biological enrollment demonstrates the feasibility of biomarker-driven cohort design and establishes a scalable model for early detection and prevention research in neurodegenerative disease. ANN NEUROL 2026.